NASDAQ · SRRKHealthcareBiotechnology

Scholar Rock Holding financials

$47.75−2.81%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$0.00$0.00$0.00$33.2M$18.8M$15.4M$20.5M—
Gross profit$0.00$0.00$0.00$33.2M$18.8M$15.4M$20.5M—
Gross margin———100.0%100.0%100.0%100.0%—
Operating income-$384.6M-$252.1M-$171.3M-$134.4M-$129.9M-$86.9M-$54.5M-$50.7M
Net income-$377.9M-$246.3M-$165.8M-$134.5M-$131.8M-$86.5M-$51.0M-$49.3M
Net margin———−405.2%−700.5%−561.5%−248.9%—
Diluted EPS$-3.29$-2.47$-1.99$-2.26$-3.59$-2.81$-1.85$-3.15
EBITDA-$383.0M-$250.1M-$168.5M-$124.5M-$127.3M-$85.4M-$53.2M-$49.9M
Operating cash flow-$300.0M-$200.9M-$145.2M-$132.7M-$126.8M-$60.3M-$63.1M$24.6M
Free cash flow-$300.6M-$201.0M-$145.3M-$133.8M-$132.0M-$64.4M-$66.2M$23.1M
Diluted shares114.7M99.8M83.3M59.6M36.7M30.7M27.5M15.7M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$323.5M$177.9M$101.9M$103.3M$212.8M$160.4M
Short-term investments$44.0M$259.4M$178.1M$212.1M$40.2M$180.7M
Total debt$99.7M$50.1M$50.0M$49.7M$50.0M$24.7M
Total assets$404.3M$474.9M$311.0M$358.2M$304.4M$388.3M
Total liabilities$158.8M$106.3M$85.8M$97.9M$132.4M$127.5M
Shareholders' equity$245.5M$368.6M$225.2M$260.2M$172.1M$260.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology